Outcomes4Me and Labcorp Study Reveals Digital Education Can Increase HER2-low Awareness for Metastatic Breast Cancer Patients
Outcomes4Me and Labcorp will present findings from their joint biomarker awareness study at the 2024 San Antonio Breast Cancer Symposium. The research focused on HER2-low awareness in metastatic breast cancer patients. The study revealed that 41.9% of patients with known HER2 status were not well-aware of HER2-low classification, and 51.3% of HER2-negative patients didn't recall discussing HER2-low with their oncologists.
Through a digital education campaign including discussion guides and webinars, the initiative showed promising results: 60.9% of patients with unknown HER2 status felt likely to discuss testing with their oncologist after engaging with the educational content. The study demonstrates how digital patient education can effectively increase biomarker awareness and encourage patient-provider discussions about testing.
Outcomes4Me e Labcorp presenteranno i risultati del loro studio congiunto sulla consapevolezza dei biomarcatori al Symposium sul Cancro della Mammella di San Antonio 2024. La ricerca si è concentrata sulla consapevolezza del HER2 basso nei pazienti con carcinoma mammario metastatico. Lo studio ha rivelato che il 41,9% dei pazienti con stato HER2 noto non era ben informato sulla classificazione del HER2 basso, e il 51,3% dei pazienti HER2-negativi non ricordava di aver discusso del HER2 basso con i propri oncologi.
Attraverso una campagna di educazione digitale che include guide di discussione e webinar, l'iniziativa ha mostrato risultati promettenti: il 60,9% dei pazienti con stato HER2 sconosciuto si sentiva propenso a discutere del test con il proprio oncologo dopo aver interagito con il contenuto educativo. Lo studio dimostra come l'educazione digitale dei pazienti possa efficacemente aumentare la consapevolezza dei biomarcatori e incoraggiare le discussioni tra pazienti e fornitori riguardo ai test.
Outcomes4Me y Labcorp presentarán los hallazgos de su estudio conjunto sobre la concienciación de biomarcadores en el Simposio de Cáncer de Mama de San Antonio 2024. La investigación se centró en la conciencia sobre HER2 bajo en pacientes con cáncer de mama metastásico. El estudio reveló que el 41,9% de los pacientes con estado HER2 conocido no estaban bien informados sobre la clasificación de HER2 bajo, y el 51,3% de los pacientes HER2 negativos no recordaban haber discutido el HER2 bajo con sus oncólogos.
A través de una campaña de educación digital que incluye guías de discusión y seminarios web, la iniciativa mostró resultados prometedores: el 60,9% de los pacientes con estado HER2 desconocido se sintieron propensos a discutir pruebas con su oncólogo después de involucrarse con el contenido educativo. El estudio demuestra cómo la educación digital para pacientes puede aumentar efectivamente la concienciación sobre biomarcadores y fomentar discusiones entre pacientes y proveedores sobre las pruebas.
Outcomes4Me와 Labcorp은 2024년 샌안토니오 유방암 심포지엄에서 공동 바이오마커 인식 연구 결과를 발표할 예정입니다. 이 연구는 전이성 유방암 환자에서 HER2-low 인식에 중점을 두었습니다. 연구 결과, HER2 상태를 알고 있는 환자의 41.9%가 HER2-low 분류에 대해 잘 알지 못하고 있었으며, HER2 음성 환자의 51.3%는 자신의 종양 전문의와 HER2-low에 대해 논의한 기억이 없었습니다.
토론 가이드와 웨비나를 포함한 디지털 교육 캠페인을 통해 이 이니셔티브는 유망한 결과를 보였습니다: HER2 상태가 알려지지 않은 환자의 60.9%가 교육 콘텐츠에 참여한 후 자신의 종양 전문의와 검사를 논의할 가능성이 있다고 느꼈습니다. 이 연구는 디지털 환자 교육이 바이오마커 인식을 효과적으로 증가시키고 검사에 대한 환자와 제공자 간의 논의를 촉진할 수 있음을 보여줍니다.
Outcomes4Me et Labcorp présenteront les résultats de leur étude conjointe sur la sensibilisation aux biomarqueurs lors du symposium de San Antonio sur le cancer du sein 2024. La recherche a porté sur la sensibilisation au HER2 faible chez les patientes atteintes de cancer du sein métastatique. L'étude a révélé que 41,9 % des patientes ayant un statut HER2 connu n'étaient pas bien informées sur la classification HER2 faible, et 51,3 % des patientes HER2 négatif ne se souvenaient pas d'avoir discuté du HER2 faible avec leurs oncologues.
Grâce à une campagne d'éducation numérique comprenant des guides de discussion et des webinaires, l'initiative a montré des résultats prometteurs : 60,9 % des patientes dont le statut HER2 est inconnu se sont dites susceptibles de discuter du test avec leur oncologue après avoir interagi avec le contenu éducatif. L'étude démontre comment l'éducation numérique des patients peut efficacement accroître la sensibilisation aux biomarqueurs et encourager les discussions entre patients et fournisseurs sur les tests.
Outcomes4Me und Labcorp werden die Ergebnisse ihrer gemeinsamen Studie zur Biomarker-Bewusstseinsbildung auf dem 2024 San Antonio Breast Cancer Symposium präsentieren. Die Forschung konzentrierte sich auf das Bewusstsein für HER2-Niedrig bei Patienten mit metastasierendem Brustkrebs. Die Studie ergab, dass 41,9 % der Patienten mit bekanntem HER2-Status nicht gut über die Klassifizierung von HER2-Niedrig informiert waren, und 51,3 % der HER2-negativen Patienten sich nicht daran erinnerten, das Thema HER2-Niedrig mit ihren Onkologen besprochen zu haben.
Durch eine digitale Bildungsinitiative, die Diskussionsleitfäden und Webinare einschloss, zeigte die Initiative vielversprechende Ergebnisse: 60,9 % der Patienten mit unbekanntem HER2-Status fühlten sich nach der Beschäftigung mit den Bildungsinhalten geneigt, mit ihrem Onkologen über Tests zu diskutieren. Die Studie zeigt, wie digitale Patientenbildung effektiv das Bewusstsein für Biomarker erhöhen und Gespräche zwischen Patienten und Anbietern über Tests fördern kann.
- None.
- None.
Research to be presented in a joint poster session with Labcorp at the 2024 San Antonio Breast Cancer Symposium
"Following the results of the DESTINY-BREAST04 trial at the American Society of Clinical Oncology meeting in 2022, HER2-low emerged as an important biomarker within metastatic breast cancer (mBC)," said Maya R. Said, Sc.D., Founder and CEO of Outcomes4Me. "We knew that many patients living with mBC would benefit from understanding their HER2-low status. We recognize the need to translate the latest clinical research into clinical practice in a timely manner, however, studies have demonstrated that there can be significant delays in disseminating new research findings for broad clinical use in the community. A key component in efficient translation of research into clinical practice is communication with all stakeholders, including patients."
"Our direct-to-patient approach gives patients the tools to have the right conversation with their doctor, in an effort to accelerate guideline-concordant care," Said continued. "We approached Labcorp to collaborate on this patient awareness program because we knew that we could help save lives by doing so."
Utilizing Outcomes4Me's direct-to-patient digital platform, Outcomes4Me and Labcorp developed an educational campaign comprised of a doctor-patient discussion guide, a live and archived webinar, and patient-friendly information and content about HER2-testing and HER2-low breast cancer.
"Labcorp is committed to ensuring that patients have access to the right tests and treatments, and self-advocacy is a key component of that," said Dr. Rebecca Previs, Director of Medical Affairs at Labcorp Oncology. "Our collaboration with Outcomes4Me was a great opportunity to connect directly with patients to empower them with the information they needed to proactively broach HER2 testing with their providers."
A pre-campaign survey found that
The results of this study affirm that patient-centric biomarker education about HER2-low both increases biomarker awareness and drives the willingness of patients to initiate a conversation around biomarker testing and HER2 status with their provider. The study highlights the benefits of collaboration between diagnostic companies and digital health platforms that directly engage patients, ultimately improving testing rates and patient outcomes. The complete poster will be on display on Friday, December 13, 2024 from 12:00-2:00pm. Outcomes4Me is also exhibiting at SABCS and will be located at Booth #1250.
About Outcomes4Me
Named a 2024 Fast Company World Changing Idea, Outcomes4Me is the first and only end-to-end, AI-driven patient empowerment platform that helps cancer patients take a proactive approach to their care from diagnosis throughout every stage of life and care. Through its patented technology, the company is on a mission to democratize healthcare by providing personalized, real-time, evidence-based information and resources to cancer patients to address their clinical and emotional needs, ensuring they can effectively navigate through their disease and improve their outcomes. In doing so, Outcomes4Me is working to promote health equity by generating deeper insights that improve care, and accelerating research and access to innovation. Based in
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for
View original content:https://www.prnewswire.com/news-releases/outcomes4me-and-labcorp-study-reveals-digital-education-can-increase-her2-low-awareness-for-metastatic-breast-cancer-patients-302316505.html
SOURCE Outcomes4Me Inc.
FAQ
What percentage of patients were unaware of HER2-low classification according to the Labcorp study?
When will Outcomes4Me present their HER2-low awareness study results at SABCS 2024?
How effective was the Outcomes4Me digital education campaign in encouraging patient-doctor discussions?
What percentage of HER2-negative patients didn't discuss HER2-low status with their oncologist?
